Thus the total ddI tablets per day were 2 and not 4. Efficacy data was available for 375 patients and safety data in 725 patients. CD4 count increased by 170 cells in both groups. The incidence of serious side effects was fairly equal in both groups. This should greatly improve tolerability and adherence to ddI containing regimens.
Fluorine makes the compound more stable in an acid environment.
There were four treatment arms. Arms 1 to 3 included regimens of d4T and indinavir in standard doses with doses of 100mg, 200mg and 300mg twice daily of lodenosine respectively. Data from 66 patients followed for 12 weeks was presented. This was not significantly different than the control arm. Mean increase in CD4 appeared to be greatest in the 100mg lodenosine arm compared to the other two arms, and equaled that of the control arm.